Bioheng Therapeutics US

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Bioheng Therapeutics US sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Bioheng Therapeutics US: 1 sponsored US clinical trial, 1 recruiting.

Bioheng Therapeutics US sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Lymphoblastic, with 1 trials.

Mid-pack sponsor footprint

Bioheng Therapeutics US is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Phase Distribution

PhaseTrial count
Phase 1 1

What is open in the Bioheng Therapeutics US pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Lymphoma, Lymphoblastic (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Bioheng Therapeutics US: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Bioheng Therapeutics US sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Bioheng Therapeutics US1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Bioheng Therapeutics US sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Bioheng Therapeutics US sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Bioheng Therapeutics US page

1 registered trials is a research-attention snapshot, not an endorsement of Bioheng Therapeutics US or any single study.

  • 1 of Bioheng Therapeutics US's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lymphoma, Lymphoblastic is the condition Bioheng Therapeutics US studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Lymphoblastic trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Bioheng Therapeutics US pipeline card: 1 registered trials from official public datasets.Report a data error.